considered definitely abnormal. The anemias, leukopenias granulocytopenias and thrombocytopenias observed in the control patients on chloramphenical therapy all subsided after the drug was discontinued. One control patient who developed anemia, thrombocytopenia and leukopenia, concurrently developed staphylococcal pneumonia and extensive phlebitis and cellulitis at the site of an intravenous polyetheylene catheter. However, as the patient's differential count remained normal, and the lowest total white blood cell count recorded was 3,100 per cmm. the superinfection was not necessarily related to the mild leukopenia.

## SUMMARY

Overall results of treatment of H. influenza meningities with ampicillin or chloramphenical appeared comparable, but no definite advantages were demonstrated in the use of ampicillin other than the freedom from hematologic depression. While one death occurred among the ampicillin group and two additional patients required neurosurgical procedures for correction of hydrocephalus, four control patients died and one had severe neurological residual. Further study, perhaps with higher dosage, is indicated.

This study was supported in part by the Hastings Foundation, and a grant from Bristol Laboratories, Syracuse, New York, U.S.A.

John M. Leedom is an Epidemic Intelligence Service Officer, Epidemiology

Branch, Communicable Disease Center, U.S. Public Health Service.

Dr. Bernard Hanes provided statistical advice.

We should like to thank Robert A. Murray for technical assistance and Drs. A. Burckin, A. Christiansen, P. Robbie and V. Spilotro for assistance in reviewing clinical data and the house staff of the Communicable Disease Service, Los Angeles County General Hospital for their co-operation and excellent care of the patients.

The diagnostic bacteriology was directed by Margaret Parrish and Patricia Hagen, in the Communicable Disease Section of the Microbiology Laboratories, Dr. Robert Clelland, Director, Los Angeles County General Hospital.

Ampicillin assays were performed by Bristol Laboratories, Syracuse, New

## REFERENCES

DOLPHIN, A., and POPHAM, R. D. (1951): Lancet, ii, 472.

DRYSDALE, C., McIntosh, D., and Brodie, J. (1946): *Brit. med. J.*, ii 223. Fothergill, L. D., and Wright, J. (1933): *J. Immunol.*, 24, 273. Haggerty, R. J., and Ziai, M. (1964): *Advanc. Pediat.*, 13, 129.

IVLER, D., THRUPP, L. D., LEEDOM, J. M., WEHRLE, P. F., and PORTNOY, B. (1963): Antimicrbial Agents and Chemotherapy—1963 p. 335, American Society of Micro-

KLEIN, J. O., and FINLAND, M. (1963): Amer. J. med. Sci., 245, 544. PLATOU, R. V. RINKER, A., and DERRICK, J. (1959): Pediatricts, 23, 962. ROLINSON, G., and STEVENS, S. (1961): Brit. med. J., ii, 191. THOMSON, J., BRUCE, L., and GREEN, M. (1947): Brit. med. J., ii, 414. ZINNEMANN, K. (1946): Brit. med. J., ii, 931.

## APPENDIX XI

[From Antimicrobial Agents and Chemotherapy, 1965, pp. 610-617]

EXPERIENCE WITH AMPICILLIN IN BACTERIAL MENINGITIS

(By Allen W. Mathies, Jr., John M. Leedom, Lauri D. Thrupp, Daniel Ivler, Bernard Portnoy, and Paul F. Wehrle)

Departments of Pediatrics, Medicine, and Microbiology, and the Hastings Foundation Infectious Disease Laboratory, University of Southern California, and the Communicable Disease Service, Los Angeles County General Hospital, Los Angeles, California

## ABSTRACT

The mortality of bacterial meningitis is 10 to 15% in large contemporary series and prompts continuing search for effective, nontoxic therapeutic agents.